The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Antimicrobial-Resistant Pathogens in Intensive Care Units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) Study, 2005-2006
Open accessAbstract
Between 1 September 2005 and 30 June 2006, 19 medical centers collected 4,180 isolates recovered from clinical specimens from patients in intensive care units (ICUs) in Canada. The 4,180 isolates were collected from 2,292 respiratory specimens (54.8%), 738 blood specimens (17.7%), 581 wound/tissue specimens (13.9%), and 569 urinary specimens (13.6%). The 10 most common organisms isolated from 79.5% of all clinical specimens were methicillin-susceptible Staphylococcus aureus (MSSA) (16.4%), Escherichia coli (12.8%), Pseudomonas aeruginosa (10.0%), Haemophilus influenzae (7.9%), coagulase-negative staphylococci/ Staphylococcus epidermidis (6.5%), Enterococcus spp. (6.1%), Streptococcus pneumoniae (5.8%), Klebsiella pneumoniae (5.8%), methicillin-resistant Staphylococcus aureus (MRSA) (4.7%), and Enterobacter cloacae (3.9%). MRSA made up 22.3% (197/884) of all S. aureus isolates (90.9% of MRSA were health care-associated MRSA, and 9.1% were community-associated MRSA), while vancomycin-resistant enterococci (VRE) made up 6.7% (11/255) of all enterococcal isolates (88.2% of VRE had the vanA genotype). Extended-spectrum β-lactamase (ESBL)-producing E. coli and K. pneumoniae occurred in 3.5% (19/536) and 1.8% (4/224) of isolates, respectively. All 19 ESBL-producing E. coli isolates were PCR positive for CTX-M, with bla CTX-M-15 occurring in 74% (14/19) of isolates. For MRSA, no resistance against daptomycin, linezolid, tigecycline, and vancomycin was observed, while the resistance rates to other agents were as follows: clarithromycin, 89.9%; clindamycin, 76.1%; fluoroquinolones, 90.1 to 91.8%; and trimethoprim-sulfamethoxazole, 11.7%. For E. coli , no resistance to amikacin, meropenem, and tigecycline was observed, while resistance rates to other agents were as follows: cefazolin, 20.1%; cefepime, 0.7%; ceftriaxone, 3.7%; gentamicin, 3.0%; fluoroquinolones, 21.1%; piperacillin-tazobactam, 1.9%; and trimethoprim-sulfamethoxazole, 24.8%. Resistance rates for P. aeruginosa were as follows: amikacin, 2.6%; cefepime, 10.2%; gentamicin, 15.2%; fluoroquinolones, 23.8 to 25.5%; meropenem, 13.6%; and piperacillin-tazobactam, 9.3%. A multidrug-resistant (MDR) phenotype (resistance to three or more of the following drugs: cefepime, piperacillin-tazobactam, meropenem, amikacin or gentamicin, and ciprofloxacin) occurred frequently in P. aeruginosa (12.6%) but uncommonly in E. coli (0.2%), E. cloacae (0.6%), or K. pneumoniae (0%). In conclusion, S. aureus (MSSA and MRSA), E. coli , P. aeruginosa , H. influenzae , Enterococcus spp., S. pneumoniae , and K. pneumoniae are the most common isolates recovered from clinical specimens in Canadian ICUs. A MDR phenotype is common for P. aeruginosa isolates in Canadian ICUs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tenover, F. C., Arbeit, R. D., Goering, R. V., Mickelsen, P. A., Murray, B. E., Persing, D. H., & Swaminathan, B. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.9.2233-2239.1995 · Cited by 8,204
Estimating Health Care-Associated Infections and Deaths in U.S. Hospitals, 2002
Klevens, R. M., Edwards, J. R., Richards, C. L., Horan, T. C., Gaynes, R. P., Pollock, D. A., & Cardo, D. M. (2007) · Public Health Reports® · doi:10.1177/003335490712200205 · Cited by 2,960
Wikler, M. A., & Clinical (2006) · Clinical and Laboratory Standards Institute eBooks · Cited by 2,843
Oliveira, D. C., & Lencastre, H. D. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.7.2155-2161.2002 · Cited by 1,343
Decreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada
Chen, D. K., McGeer, A., de Azavedo, J. C., & Low, D. E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410403 · Cited by 987
Increasing Prevalence of Multidrug-Resistant Streptococcus pneumoniae in the United States
Whitney, C. G., Farley, M. M., Hadler, J., Harrison, L. H., Lexau, C., Reingold, A., Lefkowitz, L., Cieslak, P. R., Cetron, M., Zell, E. R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432603 · Cited by 888
Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community
Pitout, J. D. D., Nordmann, P., Laupland, K. B., & Poirel, L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki166 · Cited by 790
Schwaber, M. J., & Carmeli, Y. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm318 · Cited by 626
Active Bacterial Core Surveillance of the Emerging Infections Program Network
Schuchat, A., Hilger, T., Zell, E., Farley, M. M., Reingold, A., Harrison, L., Lefkowitz, L., Danila, R., Stefonek, K., Barrett, N., et al. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0701.010114 · Cited by 592
Doern, G. V., Heilmann, K. P., Huynh, H. K., Rhomberg, P. R., Coffman, S. L., & Brueggemann, A. B. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1721-1729.2001 · Cited by 538
Community-Associated MRSA — Resistance and Virulence Converge
Chambers, H. F. (2005) · New England Journal of Medicine · doi:10.1056/nejme058023 · Cited by 423
Lockhart, S. R., Abramson, M. A., Beekmann, S. E., Gallagher, G., Riedel, S., Diekema, D. J., Quinn, J. P., & Doern, G. V. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01284-07 · Cited by 396
Deshpande, L. M., Fritsche, T. R., Moet, G. J., Biedenbach, D. J., & Jones, R. N. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.12.022 · Cited by 345
Huang, S. S., Yokoe, D. S., Hinrichsen, V. L., Spurchise, L. S., Datta, R., Miroshnik, I., & Platt, R. (2006) · Clinical Infectious Diseases · doi:10.1086/507636 · Cited by 286
Mulvey, M. R., Chui, L., Ismail, J., Louie, L., Murphy, C., Chang, N., Alfa, M., & the Canadian Committee for the Standardization of Molecular Methods (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.10.3481-3485.2001 · Cited by 254
Self-citationLewis, J. S., Herrera, M., Wickes, B., Patterson, J. E., & Jorgensen, J. H. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00576-07 · Cited by 231
Gilbert, M. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.051565 · Cited by 187
Mulvey, M. R., Bryce, E., Boyd, D. A., Ofner-Agostini, M., Christianson, S., Simor, A. E., & Paton, S. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1204-1214.2004 · Cited by 152
Self-citationPitout, J. D. D., Church, D. L., Gregson, D. B., Chow, B. L., McCracken, M., Mulvey, M. R., & Laupland, K. B. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01377-06 · Cited by 144
Self-citationCommunity-associated Methicillin-resistantStaphylococcus aureus, Canada
Mulvey, M. R., MacDougall, L., Cholin, B., Horsman, G. B., Fidyk, M., Woods, S., & the Saskatchewan CA-MRSA Study Group (2005) · Emerging infectious diseases · doi:10.3201/eid1106.041146 · Cited by 133
Self-citationMoland, E. S., Hanson, N. D., Black, J. A., Hossain, A., Song, W., & Thomson, K. S. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00756-06 · Cited by 126
Fridkin, S. K., Edwards, J. R., Tenover, F. C., Gaynes, R. P., McGowan, J. E., & Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project (2001) · Clinical Infectious Diseases · doi:10.1086/321893 · Cited by 115
Rhomberg, P. R., Fritsche, T. R., Sader, H. S., & Jones, R. N. (2006) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.12.009 · Cited by 101
Anti-infective research and development—problems, challenges, and solutions
Bradley, J. S., Guidos, R., Baragona, S., Bartlett, J. G., Rubinstein, E., Zhanel, G. G., Tino, M. D., Pompliano, D. L., Tally, F., Tipirneni, P., et al. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70689-2 · Cited by 99
Self-citationComparative Genomics of Canadian Epidemic Lineages of Methicillin-Resistant Staphylococcus aureus
Christianson, S., Golding, G. R., Campbell, J., & Mulvey, M. R. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.02500-06 · Cited by 96
Self-citationEsposito, S., & Leone, S. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.10.017 · Cited by 79
Surveillance for Vancomycin-Resistant Enterococci: Type, Rates, Costs, and Implications
Shadel, B. N., Puzniak, L., Gillespie, K. N., Lawrence, S. J., Kollef, M. H., & Mundy, L. M. (2006) · Infection Control and Hospital Epidemiology · doi:10.1086/507960 · Cited by 46
Ylipalosaari, P., Ala-Kokko, T. I., Laurila, J., Ohtonen, P. P., & Syrjälä, H. (2006) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2006.01135.x · Cited by 41
Farr, B. M. (2006) · Infection Control and Hospital Epidemiology · doi:10.1086/508759 · Cited by 36
Zhanel, G. G., DeCorby, M. R., Nichol, K. A., Baudry, P. J., Karlowsky, J. A., Lagacé-Wiens, P. R. S., McCracken, M., Mulvey, M. R., Hoban, D. J., & The Canadian Antimicrobial Resistance Alliance (2008) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2008/714846 · Cited by 31
Self-citation
Cited by
Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use
Dalhoff, A. (2012) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2012/976273 · Cited by 354
Rotstein, C., Evans, G., Born, A., Grossman, R., Light, R. B., Magder, S., McTaggart, B., Weiss, K., & Zhanel, G. G. (2008) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2008/593289 · Cited by 282
Self-citationAlkofide, H., Alhammad, A. M., Alruwaili, A., Aldemerdash, A., Almangour, T. A., Alsuwayegh, A., Almoqbel, D., Albati, A., Alsaud, A., & Enani, M. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s283488 · Cited by 96
Metadata
- Authors
- Zhanel, G. G., DeCorby, M., Laing, N., Weshnoweski, B., Vashisht, R., Tailor, F., Nichol, K. A., Wierzbowski, A., Baudry, P. J., Karlowsky, J. A., Lagacé-Wiens, P., Walkty, A., McCracken, M., Mulvey, M. R., Johnson, J., The Canadian Antimicrobial Resistance Alliance (CARA), & Hoban, D. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-04
- Volume
- 52
- Issue
- 4
- Pages
- 1430-1437
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1970698892
- Cited by
- 271
- References
- 30
- FWCI
- 12.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.